Search Within

Lindsey Elizabeth Roeker

Formats
  1. Meeting Abstract (82)
  2. Journal Article (43)
  3. Research Letter (11)
  4. Review (5)
  5. Editorial (4)
  6. Book Section (1)
Groups
  1. Department of Medicine (146)
  2. Hematologic Malignancies, Division of (146)
  3. Hematology-Oncology Fellows (146)
  4. Center for Hematologic Malignancies (108)
  5. Adult Leukemia (104)
  6. GME, Medicine (43)

More Groups

People
  1. Anthony Mato (94)
  2. Meghan Thompson (37)
  3. Andrew Zelenetz (34)
  4. Omar Abdel-Wahab (16)
  5. Mark Geyer (15)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (15)
  2. 2024 (20)
  3. 2023 (24)
  4. 2022 (24)
  5. 2021 (21)
  6. 2020 (21)

More Years

Publications
  1. Blood (58)
  2. Leukemia and Lymphoma (11)
  3. British Journal of Haematology (8)
  4. Blood Advances (7)
  5. Clinical Lymphoma, Myeloma and Leukemia (7)
  6. Journal of Clinical Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (66)
  2. Taylor & Francis Group (11)
  3. Elsevier Inc. (8)
  4. John Wiley & Sons (8)
  5. American Society of Clinical Oncology (7)
  6. S. Karger AG (7)

More Publishers

Results (146)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
    Journal Article

    Roeker, L. E.; DerSarkissian, M.; Ryan, K.; Chen, Y.; Duh, M. S.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
    Blood Advances (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Eyre, T. A.; Thompson, P.; Wierda, W. G.; Šimkovič, M.; Grosicki, S.; Jurczak, W.; Wang, Y.; Móciková, H.; Zinzani, P. L.; Tam, C. S. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Follows, G.; Burke, J. M.; Grosicki, S.; Chen, C.; Sanna, A.; Roeker, L. E.; Yi, S.; Munir, T.; de la Cruz, F.; Ferrant, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
    Journal Article

    Eyre, T. A.; Hess, L. M.; Sugihara, T.; He, D.; Khanal, M.; Pagel, J. M.; Walgren, R. A.; Abada, P. B.; Konig, H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Treatment discontinuation patterns for patients with chronic lymphocytic leukemia in real-world settings: Results from a multi-center international study
    Journal Article

    Shadman, M.; Manzoor, B. S.; Sail, K.; Tuncer, H. H.; Allan, J. N.; Ujjani, C.; Emechebe, N.; Kamalakar, R.; Coombs, C. C.; Leslie, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical experience with drugs targeting Bruton's Tyrosine Kinase (BTK)
    Book Section

    Aronson, J.; Mato, A. R.; Coombs, C. C.; Islam, P.; Roeker, L. E.; Eyre, T.
    In O'Connor, O. A.; Ansell, S. M.; Seymour, J. F. (Eds.) Precision Cancer Therapies (2023)

    Fulltext@MSK | Save
  • Clonal characterization and somatic hypermutation assessment by next-generation sequencing in chronic lymphocytic leukemia/small lymphocytic lymphoma: A detailed description of the technical performance, clinical utility, and platform comparison
    Journal Article

    Petrova-Drus, K.; Syed, M.; Yu, W.; Hutt, K.; Zlotnicki, A. M.; Huang, Y.; Kamalska-Cyganik, M.; Maciag, L.; Wang, M.; Ma, Y. G.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: Identifying risk factors to help guide treatment selection
    Journal Article

    Bantilan, K. S.; Kay, N. E.; Parikh, S. A.; Rabe, K. G.; Call, T. G.; Leis, J. F.; Ding, W.; Slager, S. L.; Soumerai, J. D.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save